Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart study seeks clues to hidden cause of chest pain in women

NCT ID NCT03537586

Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some women with chest pain or signs of heart disease have normal-looking large arteries but still have problems with tiny blood vessels in the heart. Researchers will measure platelet activity and inflammation during a heart catheterization to see if these factors are linked to microvascular dysfunction. The goal is to find better ways to diagnose and understand this condition, which affects up to 40% of women with stable heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify non-invasive ways to diagnose coronary microvascular dysfunction and point toward new treatment targets.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly benefit participants. The findings may not apply to men or other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

206 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 125 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult women age ≥18 years referred for coronary angiography * Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia by stress testing * Administration of aspirin therapy prior to cardiac catheterization Exclusion Criteria: Pre-Cath Exclusion criteria: * Active bleeding and/or bleeding diathesis * Anemia (hemoglobin \<9 mg/dl) * Known thrombocytosis (platelet count \>500,000) * Know thrombocytopenia (platelet count \<100,000) * NSAIDs (e.g., ibuprofen, naproxen) within 3 days * Platelet antagonists other than aspirin and thienopyridines, within 7 days * Prior percutaneous coronary intervention or coronary artery bypass grafting * Acute myocardial infarction within 3 months * Severe valvular heart disease * Cardiogenic shock or mechanical circulatory support * New York Heart Association (NYHA) Functional Class III or IV heart failure * Ejection Fraction \<40% * Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy * Pregnancy * Contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia, Angiographic Exclusion criteria: * Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography) * Unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or PI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary microvascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder Microvascular Angina myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary microvascular disease Ischemic heart disease Myocardial ischemia

Contacts and locations

Locations

  • New York University School of Medicine

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.